Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle

IDrugs

Volumn 9, Issue 4, 2006, Pages 273-278

  Thomas, Mark P ^a   McInnes, Campbell ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Cancer therapeutics; CDK inhibitors; Cell cycle; Cyclin dependent kinases (CDKs); Drug discovery; Structure based design; Virtual screening

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; FASCAPLYSIN; FLAVOPIRIDOL; ROSCOVITINE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CELL CYCLE; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; IC 50; IN VIVO STUDY; PREDICTION; PROTEIN DATA BANK; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646052849     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Congreve M, Murray CW, Blundell TL: Structural biology and drug discovery. Drug Discovery Today (2005) 10(13):895-907.
2. Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 36(3):131-149.
3. Fischer PM, Gianella-Borradori A: Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Invest Drugs (2005) 14(4):457-477.
4. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P et al: Discovery of a novel family of CDK inhibitors with the program LIDAEUS: Structural basis for ligand-induced disordering of the activation loop. Structure (2003) 11(4):399-410.
5. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G et al: 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem (2004) 47(7):1662-1675.
6. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP et al: Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol (2004) 11(4):525-534.
7. Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM: Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol (2006) 13(2):201-211.